Material Transfer Agreement (MTA) in New Zealand

If your business is sending or receiving biological samples, research materials, prototypes, data-linked specimens, cell lines, reagents, seeds, or other tangible research inputs, a material transfer agreement (MTA) is often the document that decides who can use the material, for what purpose, and who owns any results. Founders and research-led SMEs often get caught by three mistakes: accepting a university or supplier template without checking IP ownership, treating the transfer like a simple supply arrangement, and relying on emails or verbal statements about permitted use.

Those errors can create expensive problems later, especially when a project turns commercial, a collaboration breaks down, or a regulator, investor, or buyer asks who has rights to the material and any improvements. The guide below explains what a material transfer agreement (MTA) usually covers in New Zealand, the main legal issues to check before you sign, and the common drafting traps that can limit your business long after the transfer takes place.

Overview

A material transfer agreement is a contract used when one party provides physical materials to another for research, testing, evaluation, or limited commercial purposes. In New Zealand, the core legal questions are usually contractual rather than driven by one single MTA statute, which means the wording matters a great deal.

The main job of the agreement is to make it clear what is being transferred, what the recipient can do with it, what happens to any results, and who carries the risk if something goes wrong.

• Define the transferred material precisely, including samples, derivatives, modifications, and associated data.
• State the permitted use, prohibited use, and whether any commercial use is allowed.
• Deal with ownership of the original material, research results, inventions, and improvements.
• Set out confidentiality obligations and how publications or disclosures are handled.
• Address compliance issues, including biosecurity, health and safety, privacy, and import or export restrictions where relevant.
• Allocate risk through warranties, liability clauses, indemnities, and the recipient's responsibility for handling and storage.
• Explain what must be returned, destroyed, or retained at the end of the project.

What Material Transfer Agreement Mta Means For New Zealand Businesses

A material transfer agreement is not just admin paperwork, it is the contract that controls a sensitive handover of valuable material. Before you sign, your business needs to know whether the material is being shared for a narrow research purpose or whether the deal could affect future product development, commercialisation, and investment value.

In practice, an MTA commonly appears in founder moments such as these:

• A biotech startup receives a cell line from a university for proof of concept work.
• An agritech business sends seed samples or plant material to a testing partner.
• A medtech company receives human-derived samples for assay development.
• A food innovation company shares cultures or formulations with an external lab.
• A manufacturer provides prototype materials to a collaborator for testing and validation.

What an MTA Usually Covers

The document usually sits somewhere between a confidentiality agreement, a licence, and a research collaboration contract. It often covers the transfer itself, but it can also quietly deal with future rights in anything created from that material.

A well-drafted MTA will usually address:

• what the material is, including batch details, quantity, and any documents or data provided with it
• whether the material remains the provider's property
• whether the recipient can test, analyse, reproduce, modify, or combine the material with other materials
• whether the material can be shared with subcontractors, affiliates, or researchers
• whether the material may only be used for internal research or may support commercial development
• whether publications require prior review or consent
• what happens to derivatives, modifications, and research outputs

Why MTAs Matter Commercially

The main commercial risk is that a short document can create a long-term restriction on your business. A provider may say the transfer is only for evaluation, but a clause on improvements could also give them rights over anything you develop using or derived from the material.

This becomes a real issue when you are raising capital or negotiating with a customer or partner. Investors and counterparties often want to know whether your business actually owns the key know-how, test results, or inventions that came out of the project.

MTAs also matter where regulated or sensitive materials are involved. If the material is hazardous, biological, human-derived, or imported, your business may need extra internal controls around storage, use, disposal, record-keeping, and who can access it.

How MTAs Interact With Other Agreements

An MTA often does not stand alone. Before you rely on the wording, check whether the transfer sits alongside other documents that change the legal position.

These may include:

• a confidentiality agreement
• a services agreement with a testing laboratory
• a research collaboration agreement
• a manufacturing or development agreement
• an intellectual property licence
• a data sharing agreement where associated data is also being provided

If these documents do not line up, founders often end up with conflicting rules on ownership, permitted use, publication rights, or liability. That is where businesses get caught before they sign a contract review, especially when the other side sends a standard form and says it is non-negotiable.

Legal Issues To Check Before You Sign

The safest approach is to treat an MTA as a high-impact contract, not a routine research form. Before you accept the provider's standard terms, make sure the agreement reflects what your business is actually doing with the material and what you need to protect.

1. Description of the Material

The agreement should clearly identify the material and anything that travels with it. Vague drafting creates disputes later about whether derivatives, extracts, cultures, progeny, modifications, or metadata are covered.

Check whether the definition includes:

• physical samples and all portions of them
• replicates, progeny, or unmodified copies
• modified versions and derivatives
• related protocols, specifications, reports, or technical information
• associated personal information or coded sample data

If the material is linked to identifiable individuals or patient information, privacy issues need special care under the Privacy Act 2020. The MTA may not be enough on its own if personal information is involved.

2. Permitted Use and Restrictions

Your permitted use clause should match the real project. If your business may later move from internal testing to product development, a narrow research-only clause can become a serious blocker.

Look closely at whether the agreement prohibits:

• commercial use
• reverse engineering or analysis
• animal or human use
• clinical or field deployment
• sharing with contractors or related companies
• further transfer to any third party

If the transfer is only for evaluation, the agreement should say so plainly. If some commercial pathway is intended, that should also be stated rather than left to assumption.

3. Intellectual Property and Improvements

IP clauses are often the most important part of an MTA. Before you sign, be clear about four separate things: ownership of the original material, ownership of derivatives or modifications, ownership of project results, and ownership of inventions or improvements.

These concepts are often bundled together, but they should not be. For example, a provider may continue to own the original material, while your business owns new inventions created through your own work, subject to a licence back or limited use rights.

Points to clarify include:

• who owns the transferred material itself
• who owns modifications or derivative materials
• who owns data, test results, and reports generated by the recipient
• who owns patentable inventions or other IP arising from use of the material
• whether either party gets an automatic licence to use the other party's results
• whether any assignment language is too broad

This is where founders often get caught by phrases such as "all improvements" or "all inventions relating to the material". Those clauses can be much wider than expected.

4. Confidentiality and Publication

Many MTAs involve sensitive know-how on both sides. The agreement should protect confidential information but still allow your team to do the work it needs to do.

If the other party is a university or research institution, publication rights may be a key issue. They may want the ability to publish results, while your business may need review rights to protect confidential information or patent filing opportunities.

A sensible clause often addresses:

• what information is confidential
• how long confidentiality lasts
• who within each organisation can access the material or information
• whether draft publications must be shared for review
• how patent-sensitive information is handled before publication

5. Compliance, Regulatory, and Ethical Issues

An MTA cannot remove legal obligations that apply to the material itself. If you are handling biological, hazardous, imported, or human-derived materials, separate compliance rules may apply.

Depending on the project, issues may include:

• workplace health and safety obligations for storage, handling, transport, and disposal
• biosecurity and import controls for incoming materials
• ethics approvals or institutional requirements for human or animal related research
• privacy compliance where samples are linked to personal information
• controls on export, overseas transfers, or restricted end uses

The agreement should also make it clear who is responsible for obtaining approvals, following lab protocols, and keeping the necessary records.

6. Warranties, Liability, and Indemnities

Many providers supply materials on an "as is" basis with very limited warranties. That is common, but the recipient should understand what risk it is taking on.

Before you rely on a verbal promise that the material is safe, viable, non-infringing, or suitable for a particular purpose, check the written terms. The MTA may disclaim exactly those points.

Focus on:

• whether the provider gives any warranty about quality, purity, viability, or accuracy of information
• whether the recipient assumes all risk of use
• whether there is an indemnity for misuse, injury, or breach of law
• whether liability is capped or excluded
• whether consequential loss is excluded

7. End of Term, Return, and Destruction

The contract should say what happens when the project ends or the agreement is terminated. That matters because your business may still hold samples, data, or embedded material in ongoing work.

Check whether you must:

• return all unused material
• destroy remaining material and certify destruction
• delete or retain related data
• stop all use immediately
• keep archival records for legal or scientific reasons

If your business needs to retain results, regulatory records, or internal research data, make sure that is expressly allowed.

8. New Zealand Governing Law and Dispute Process

The agreement should have a workable governing law and dispute clause. If the provider is overseas, standard terms may nominate a foreign legal system and court process that is expensive and impractical for a New Zealand SME.

That does not always mean the clause must be changed, but it should be a conscious decision. Before you sign, weigh the legal cost of enforcing your rights against the value of the project.

Common Mistakes With Material Transfer Agreement Mta

Most MTA problems come from treating the transfer as informal or temporary. The rights granted or given away can outlast the project by years.

Accepting a One-Sided Template Without Reading the IP Clauses

This is probably the most common mistake. A founder is focused on getting samples in the door and assumes the document is a standard lab form, but the wording gives the provider rights over outputs, improvements, or commercial use.

If the project could influence future products, patents, or know-how, those clauses deserve close attention.

Leaving "Commercial Use" Undefined

Businesses often assume internal R&D is not commercial because no sales are happening yet. The provider may take a wider view, especially if the research supports a product pipeline, investment round, or customer validation process.

The contract should define what is and is not permitted, rather than leaving that debate for later.

Forgetting About Contractors and Group Companies

Many SMEs use contract labs, specialist advisers, university partners, or offshore affiliates. An MTA may prohibit any third-party access unless the provider approves it first.

If your real operating model relies on external support, the agreement needs to reflect that before you sign.

Overlooking Data and Privacy Issues

Some transfers involve more than physical materials. If coded sample information, patient-linked information, or research datasets are included, privacy and data protection questions can sit outside the obvious MTA clauses.

A business should be clear about what information is being transferred, whether it is personal information, and what additional permissions or safeguards are needed.

Ignoring Disposal, Return, and Ongoing Use

Teams often focus on getting access to the material and forget about project closeout. Then the provider asks for destruction certificates, while the recipient still needs records, test results, or retained reference samples.

That issue is much easier to solve in the drafting than after the relationship turns tense.

Assuming an MTA Covers the Whole Relationship

An MTA may be too narrow if the parties are really collaborating on a broader programme. If there are milestones, deliverables, fees, jointly developed IP, publication plans, or future commercial rights, a separate collaboration or development agreement may also be needed.

Using the wrong contract structure is a common reason businesses end up with gaps or inconsistent obligations.

FAQs

Is a material transfer agreement legally binding in New Zealand?

Yes, if it is properly drafted and agreed, an MTA is generally enforceable as a contract in New Zealand. Its effect depends on the exact wording and the surrounding circumstances.

Who owns discoveries made using transferred material?

There is no automatic rule that always applies. Ownership depends on the contract, especially the clauses dealing with results, inventions, derivatives, and improvements.

Do we need a separate confidentiality agreement as well as an MTA?

Sometimes yes. Some MTAs contain enough confidentiality protection, but others are narrower and may not cover all background information, data sharing, or pre-contract discussions.

Can we use transferred material for commercial product development?

Only if the agreement allows it. Many MTAs restrict use to internal research or evaluation, so commercial development should be expressly addressed before you sign.

What if the other side sends an overseas MTA template?

You should check the governing law, liability, IP ownership, and compliance assumptions carefully. Overseas templates often contain positions that do not fit a New Zealand SME's practical or legal needs.

Key Takeaways

• A material transfer agreement (MTA) controls how valuable materials can be used, who owns outputs, and who carries the risk.
• The most important clauses usually deal with permitted use, IP ownership, confidentiality, compliance, and end-of-project return or destruction.
• Provider templates often favour the provider, especially on commercial use, improvements, warranties, and liability.
• If personal information, human-derived materials, hazardous substances, or imported biological materials are involved, extra legal and operational checks may be needed.
• An MTA may not be enough on its own if the parties are also sharing confidential information, providing services, or collaborating on broader development work.

If you want help with IP ownership, confidentiality terms, liability allocation, compliance clauses, you can reach us on 0800 002 184 or team@sprintlaw.co.nz for a free, no-obligations chat.